Nanochon, a orthopedic device biotech company secures $4million in its series seed prime round funding. A number of investors, including Cultivate (MD), Alumni Venture Group, and Mountain State Capital, participated in the round, which was headed by The University of Virginia Licensing and Ventures Group Seed Fund.
Mountain State Capital, Cultivate (MD), Alumni Venture Group, and University of Virginia Licensing are involved in the Ventures Group Seed Fund.
The business plans to enhance research and development operations, broaden its patent portfolio, hire more people, and launch its first in-person clinical trials in the US in 2024 using the money raised.
Read also – Sweden-based EQT to acquired WSO2
Nanochon is a biotech and medical device firm dedicated on creating cutting-edge orthopedic treatments. Ben Holmes is the CEO and co-founder of the company. ChondrograftTM is a minimally invasive implant that enables rapid mobility and weight bearing, reducing the amount of time needed for recovery.
This year, the business will launch a phase I study in the US for its exclusive knee implant, ChondrograftTM. To avoid the need for expensive and time-consuming total knee replacements, the gadget simply needs minimally invasive surgery to regenerate broken bone and cartilage.
About Nanochon
The goal of Nanochon is to provide a novel method of treating cartilage loss and repair so that the hundreds of thousands of young, active patients who suffer from knee injuries may resume their normal lives without having to have intrusive, expensive short-term procedures performed. Their device, which was founded in 2016, is a minimally invasive early intervention that may help prevent the need for a total knee replacement. Total joint replacement is now the gold standard for treating joint problems in clinical practice.
